{
    "clinical_study": {
        "@rank": "129370", 
        "arm_group": {
            "arm_group_label": "Dose A", 
            "arm_group_type": "Experimental", 
            "description": "Dose A: Botulinum toxin type A"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the long-term safety of botulinum toxin type A for the treatment of\n      moderate to severe crow's feet lines after repeat application."
        }, 
        "brief_title": "Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Skin Aging", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Moderate to severe crow's feet lines\n\n          -  Female or male, 18 years of age and above and in good general health\n\n          -  Women of childbearing potential must agree to use an effective method of birth\n             control during the course of the study\n\n        Exclusion Criteria:\n\n          -  Any neurological condition that may place the subject at increased risk with exposure\n             to botulinum toxin type A\n\n          -  Muscle weakness or paralysis, particularly in the area receiving study treatment\n\n          -  Active skin disease or irritation at the treatment area\n\n          -  Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated\n             by manually spreading the skin apart\n\n          -  Treatment with botulinum toxin type A for crow's feet lines in the last 3 months\n\n          -  Chemical peel during the 9 months prior to treatment\n\n          -  Use of prescription retinoid products during the 3 months prior to treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "311", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818076", 
            "org_study_id": "RT001-CL023"
        }, 
        "intervention": {
            "arm_group_label": "Dose A", 
            "description": "Botulinum toxin type A, Dose A applied to the lateral canthal area", 
            "intervention_name": "Botulinum Toxin Type A", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37203"
                }, 
                "name": "Nashville Centre for Laser and Facial Surgery"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidences of treatment-emergent adverse events and serious treatment-emergent adverse events when the drug product is administered in repeated treatments", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Incidences of treatment-emergent laboratory, skin erythema, cranial nerve, and ocular irritation abnormalities when the drug product is administered in repeated treatments", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818076"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Revance Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Revance Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014", 
        "why_stopped": "Sponsor decision to terminate study (not due to safety reasons)"
    }
}